Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Irene M. Ghobrial"'
Publikováno v:
The Hematologist. 16
Autor:
Michelle E. Maglio, Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Elizabeth O'Donnell, Irene M. Ghobrial, Kenneth C. Anderson, Claudia E. Paba-Prada, Matthew Weinstock, Noopur Raje, Wanling Xie, Robert L. Schlossman, Constantine S. Mitsiades, Edie Weller, Diane Warren, Cindy Varga
Publikováno v:
British Journal of Haematology. 169:843-850
Summary Proteasome inhibitors (PI) and immunomodulatory agents (IMIDs) have improved the overall survival (OS) of patients with multiple myeloma (MM), but concerns have been raised about increased incidence of extramedullary disease (EMD) after the c
Autor:
Gullu Gorgun, Michelle E. Maglio, Cindy Varga, Constantine S. Mitsiades, Irene M. Ghobrial, Noopur Raje, Anna Guidetti, Mary McKenney, Robert L. Schlossman, Claudia Paba Prada, Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Deborah Doss, Jacob P. Laubach
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1089-1108
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is uniq
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
Peter Sabbatini, Stacey Chuma, Alexandra Savell, Patrick Henrick, Irene M. Ghobrial, Kenneth C. Anderson, Jacob P. Laubach, Chia Jen Liu, Kaitlen Reyes, Raymond P. Perez, Paul G. Richardson, Pamela S. Becker, Kalvis Hornburg
Publikováno v:
Blood. 132:3263-3263
Background : CXCR4 is a chemokine receptor over-expressed on > 75% of cancers, including malignant plasma cells. Ulocuplumab (BMS- 936564) is a first in class, fully human IgG4 monoclonal anti-CXCR4 antibody which inhibits the binding of CXCR4 to CXC
Autor:
Kenneth C. Anderson, Donna Neuberg, Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Daniel Auclair, Kalvis Hornburg, Mark Bustoros, Tarek H. Mouhieddine, Irene M. Ghobrial, Brendan Reardon, Muhieddine M. Itani, Robert L. Schlossman, Jacob P. Laubach, Jerome Ritz, Jihye Park, Daisy Huynh, Salomon Manier, Chia Jen Liu, Paul G. Richardson, Nikhil C. Munshi, Christopher J. Gibson, Robert J. Soiffer, Eliezer M. Van Allen, Benjamin L. Ebert, Saud H. AlDubayan, Henry Dumke, Cody J. Boehner, Robert A. Redd, Amin Nassar, David P. Steensma
Publikováno v:
Blood. 132:749-749
Introduction: Multiple Myeloma (MM) is a clonal plasma cell malignancy, accounting for 10% of all hematological malignancies. Genetic analyses of large populations revealed that blood-specific somatic mutations in hematopoietic stem cells (HSCs) are
Autor:
Sandra Wear, Irene M. Ghobrial, Daniel C. Sullivan, Nora Loughney, Lisa A. Nardelli, David S. Siegel, Robert L. Schlossman, Min Chen, Melissa Alsina, Paul G. Richardson, Susan L. Kelley, Palka Anand, Elizabeth Bilotti, Gail Larkins, Kenneth C. Anderson, M. Zaki, Jacob P. Laubach, Nikhil C. Munshi, Christian Jacques, Deborah Doss, Laura McBride, Rachid Baz
Publikováno v:
Blood. 121:1961-1967
This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles,
Autor:
Irene M. Ghobrial, Giada Bianchi
Publikováno v:
Leukemia & Lymphoma. 54:229-241
The prognosis of patients with multiple myeloma (MM) has radically changed over the past two decades mostly due to the introduction of novel pharmacologic treatments such as thalidomide, bortezomib and lenalidomide. These drugs were the first new ant
Autor:
Constantine S. Mitsiades, Mary McKenney, Teru Hideshima, Katherine Redman, Robert L. Schlossman, Paul G. Richardson, Kathleen Colson, Diane Warren, Irene M. Ghobrial, Laura E. Lunde, Nikhil C. Munshi, Kimberly Noonan, Deborah Doss, Kenneth C. Anderson, Jacob P. Laubach
Publikováno v:
European Journal of Haematology. 88:446-449
We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date. The
Autor:
Constantine S. Mitsiades, Nikhil C. Munshi, Kimberly Noonan, Jacob P. Laubach, Paul G. Richardson, Robert L. Schlossman, Irene M. Ghobrial, Katherine Redman, Kenneth C. Anderson, Mahmoud R. Gaballa
Publikováno v:
Expert Review of Hematology. 5:51-68
Multiple myeloma (MM) is a plasma cell neoplasm often associated with renal impairment (RI), with myeloma cast nephropathy recognized as the most common cause. While RI is present in over 50% of MM patients at some point in their disease course, it i